Literature DB >> 15763439

Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells.

Gareth Watkins1, Tracey A Martin, Richard Bryce, Robert E Mansel, Wen G Jiang.   

Abstract

SPARC (secreted protein acidic and rich in cystein), also known as osteonectin and BM40, is a secreted glycoprotein. It confers matrix adhesion of cells including cancer cells, thus promoting cell migration. SPARC has been shown to be involved in the aggressive nature of cancer. The current study investigated the role of a n-6 polyunsaturated fatty acid, gamma linolenic acid (GLA) on the expression and secretion of SPARC from cancer cells. Human breast cancer cell line MCF-7 and MDA-MB-231, human colon cancer cells HT115 and HRT-18 were used in the study. Cancer cells were treated with GLA or other fatty acids over a range of concentrations. Presence of SPARC in the supernatant and in the cell lysate were analysed using Western blotting. Cellular SPARC was also assessed using immunocytochemistry. SPARC transcript in these cells were studied using RT-PCR. Cell-matrix adhesion was determined using a cell-matrix adhesion assay and cell migration analysis. Treatment of MDA-MB-231 and HT115 cells with GLA, at non-toxic levels, resulted in reduction of SPARC in supernatant as well as in the cell lysate. In contrast, there were little changes in the supernatant SPARC in MCF-7 and in HRT-18 cells. Cellular SPARC, as revealed by immunocytochemistry, also demonstrated a similar trend of changes as seen with protein blotting. Analysis of the SPARC transcript using RT-PCR has shown an up-regulation of SPARC mRNA by the fatty acid. GLA reduced cell-matrix adhesion in these cancer cells. It is concluded that GLA is a regulator of SPARC secretion and expression in cancer cells. It reduces the secretion of SPARC into surrounding environment, which may contribute to the reduction of cancer cells adhesion to the extracellular matrix and cell motility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763439     DOI: 10.1016/j.plefa.2004.12.004

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  8 in total

1.  Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  Mol Cancer Ther       Date:  2014-03-07       Impact factor: 6.261

2.  Modulation of plasma and urine metabolome in colorectal cancer survivors consuming rice bran.

Authors:  Iman Zarei; Renee C Oppel; Erica C Borresen; Regina J Brown; Elizabeth P Ryan
Journal:  Integr Food Nutr Metab       Date:  2019-04-05

3.  Annexin-A1 deficiency attenuates stress-induced tumor growth via fatty acid metabolism in mice: an Integrated multiple omics analysis on the stress- microbiome-metabolite-epigenetic-oncology (SMMEO) axis.

Authors:  Jianzhou Cui; Karishma Sachaphibulkij; Wen Shiun Teo; Hong Meng Lim; Li Zou; Choon Nam Ong; Rudi Alberts; Jinmiao Chen; Lina H K Lim
Journal:  Theranostics       Date:  2022-05-09       Impact factor: 11.600

4.  LC/ESR/MS study of spin trapped carbon-centred radicals formed from in vitro lipoxygenase-catalysed peroxidation of gamma-linolenic acid.

Authors:  Qingfeng Yu; Zhen Shan; Kunyi Ni; Steven Y Qian
Journal:  Free Radic Res       Date:  2008-05

5.  Transcriptomic landscape of breast cancers through mRNA sequencing.

Authors:  Jeyanthy Eswaran; Dinesh Cyanam; Prakriti Mudvari; Sirigiri Divijendra Natha Reddy; Suresh B Pakala; Sujit S Nair; Liliana Florea; Suzanne A W Fuqua; Sucheta Godbole; Rakesh Kumar
Journal:  Sci Rep       Date:  2012-02-14       Impact factor: 4.379

Review 6.  Multiple roles of dihomo-γ-linolenic acid against proliferation diseases.

Authors:  Xiaoping Wang; Huanping Lin; Yan Gu
Journal:  Lipids Health Dis       Date:  2012-02-14       Impact factor: 3.876

7.  Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma.

Authors:  Chi-Tung Cheng; Yin-Yi Chu; Chun-Nan Yeh; Shih-Chiang Huang; Ming Huang Chen; Shang-Yu Wang; Chun-Yi Tsai; Kun-Chun Chiang; Yen-Yang Chen; Ming-Chun Ma; Chien-Ting Liu; Tsung-Wen Chen; Ta-Sen Yeh
Journal:  Onco Targets Ther       Date:  2015-07-28       Impact factor: 4.147

Review 8.  Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.

Authors:  Marwan Al-Hajeili; Asfar S Azmi; Minsig Choi
Journal:  Onco Targets Ther       Date:  2014-02-04       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.